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Processing of microRNA primary transcripts (pri-
miRNAs) is highly regulated and defects in the pro-
cessingmachinery play a key role inmany human dis-
eases. In 22q11.2 deletion syndrome (22q11.2DS),
heterozygous deletion of DiGeorge critical region
gene 8 (DGCR8) causes a processing deficiency,
which contributes to abnormal brain development.
TheDGCR8protein is theRNA-bindingpartner ofDro-
sha RNase, both essential for processing canonical
pri-miRNAs.To identify anagent that cancompensate
reducedDGCR8expression,wescreened formetallo-
porphyrins that can mimic the natural DGCR8 heme
cofactor. We found that Co(III) protoporphyrin IX
(PPIX) stably binds DGCR8 and activates it for pri-
miRNA processing in vitro and in HeLa cells. Impor-
tantly, treating cultured Dgcr8+/– mouse neurons
with Co(III)PPIX can compensate the pri-miRNA pro-
cessing defects. Co(III)PPIX is effective at concentra-
tions as low as 0.2 mM and is not degraded by heme
degradation enzymes, making it useful as a research
tool and a potential therapeutic.
INTRODUCTION
MicroRNA (miRNA) primary transcript (pri-miRNA) processing
defects have been reported in a range of human diseases,
including cancer and schizophrenia (Beveridge and Cairns,
2012; Merritt et al., 2008). A critical contribution of these defects
to pathogenesis has been demonstrated (Kumar et al., 2007;
Mori et al., 2014). In 22q11.2 deletion syndrome (also known
as DiGeorge syndrome), the DGCR8 (called Pasha in Drosophila
and Pash-1 in C. elegans) gene is heterozygously deleted along
with 30–60 other genes in chromosome 22q11 (Karayiorgou
et al., 2010; Shiohama et al., 2003). The haploinsufficiency ofChemistry & Biology 22,DGCR8 reduces the abundance of DGCR8 protein, resulting
in lower pri-miRNA processing efficiency and abnormal expres-
sion of a subset of miRNAs (Stark et al., 2008). The miRNA
deficiency has a pronounced effect on brain development and
function and contributes to the cognitive and behavioral deficits
of 22q11.2DS (Fenelon et al., 2011; Schofield et al., 2011; Stark
et al., 2008). The DGCR8 protein and Drosha form the Micropro-
cessor complex. They cooperate to recognize and cleave pri-
miRNAs, thereby producing precursor miRNAs (pre-miRNAs)
as intermediates (Denli et al., 2004; Gregory et al., 2004; Han
et al., 2004; Landthaler et al., 2004). After this initial step in
the canonical miRNA maturation pathway, pre-miRNAs are
exported to the cytoplasm and are further cleaved by the
Dicer nuclease to generate mature miRNA strands, which are
eventually incorporated into the miRNA-induced silencing
complex and become functional in gene regulation (Ha and
Kim, 2014).
To restore miRNA processing in 22q11.2DS and other dis-
eases, it is highly desirable to enhance the activity of DGCR8pro-
tein using small molecule agents, rather than engaging in risky
gene therapies. DGCR8 has been shown to be regulated by
cofactor binding, phosphorylation, acetylation, and proteolytic
cleavage (Gong et al., 2012; Herbert et al., 2013; Wada et al.,
2012; Weitz et al., 2014). These posttranslational modifications
offer opportunities for intervention. This study takes advantage
of the fact that DGCR8 is activated by the cofactor heme b
(Barr et al., 2012; Barr et al., 2011; Faller et al., 2007). A purified
recombinant DGCR8 construct NC1 (amino acids 276–751 of
the 773 amino acid full-length protein) forms a stable complex
with Fe(III) heme but binds Fe(II) heme with much weaker affinity
(Barr et al., 2011, 2012). Fe(III) heme inDGCR8 is coordinatedbya
unique two-cysteine configuration (Barr et al., 2011). DGCR8
binds heme using an RNA-binding heme domain (Rhed) that
directly contacts pri-miRNAs and cooperates with two double-
stranded RNA-binding domains to achieve high-affinity binding
and specific recognition (Quick-Cleveland et al., 2014; Senturia
et al., 2010). In cells, DGCR8 mutants that are unable to bind
heme are unable to process pri-miRNAs (Weitz et al., 2014). In
addition, DGCR8 activity can be modulated by removing heme793–802, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 793
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Figure 1. Metalloporphyrins that Were Tested for Association with
DGCR8 and for Activation of Pri-miRNA Processing
(A) Schematic of a metalloprotoporphyrin IX. The M at the center represents a
metal ion.
(B) A section of the periodic table showing the elements used in this study, with
the group numbers labeled. The protoporphyrin IX complexes with the metals
shown in red background stably bind to DGCR8, whereas the complexes with
the elements in gray do not.from the cell culture medium, adding back exogenous heme, or
inhibiting endogenous heme biosynthesis (Weitz et al., 2014).
It is well known that excess amounts of freely available heme in
cells are degraded by heme oxygenases (Kikuchi et al., 2005),
making heme less useful as a sustainable activator for pri-miRNA
processing. In this study, we set out to identify heme analogs
that are capable of binding and activating DGCR8. We either
removed the central Fe of heme or substituted it with a diverse
set of other metals. We successfully identified one such deriva-
tive, Co(III)PPIX, and demonstrated that it can rescue miRNA
expression in Dgcr8+/– mouse neurons. CoPPIX is not degraded
by heme oxygenases and thereby should be able to activate pri-
miRNA processing for a prolonged period.
RESULTS
A Metal Ion Is Necessary for Porphyrin to Stably
Associate with DGCR8
We examined potential interaction of porphyrin compounds with
heme-free (apo) forms of DGCR8 via titration and electronic ab-
sorption spectroscopy. Size exclusion chromatography (SEC)
was used to confirm the interaction and to estimate the stability
of the complexes. Two apoDGCR8 proteins were used in the
binding study: wild-type apoNC1 and the apoNC1-P351A
mutant. NC1-P351A can be conveniently purified as a heme-
free dimer (apoNC1-P351A) when recombinantly expressed in
E. coli without the addition of d-aminolevulinic acid to the me-
dium (Barr et al., 2011). apoNC1-P351A can bind Fe(III) heme
to form a stable complex similar to native Fe(III) heme-bound
NC1. The porphyrin-binding assays using apoNC1-P351A
were performed at pH 8, at which this protein is stable. This
pH is close to physiological and is routinely used for our recon-
stituted pri-miRNA processing assays (Barr and Guo, 2014). In
contrast, the porphyrin-binding assays using wild-type apoNC1
were performed at pH 6, because this protein is not very soluble794 Chemistry & Biology 22, 793–802, June 18, 2015 ª2015 Elsevierat pH 8. Wild-type NC1 is expressed in E. coli as the Fe(III) heme-
bound form and it associates with Fe(III) heme very tightly (Barr
et al., 2011). Thus, the preparation of apoNC1 requires several
additional steps after purification of NC1, including buffer ex-
change to pH 6, heme reduction, incubation with apomyoglobin
to scavenge the Fe(II) (ferrous) heme fast-dissociating fromNC1,
and SEC to separate apoNC1 from myoglobin (Barr et al., 2012),
thereby resulting in a lower yield. apoNC1 dimer prepared this
way can bind Fe(III) heme and be activated for pri-miRNA pro-
cessing (Barr et al., 2012). Because of the comparative ease of
preparation and handling, we chose to use apoNC1-P351A for
initial binding assays with porphyrins. The binding or lack of
binding for select porphyrins was confirmed using wild-type
apoNC1.
We first tested protoporphyrin IX (PPIX), which does not
contain a metal center (Figure 1A). Incubation of PPIX with
apoNC1-P351A dimer resulted in a predominant So¨ret peak at
383 nm, which was slightly shifted from the 377-nm peak of
PPIX without DGCR8 (Figure S1A). The peak wavelengths and
shape of the spectra did not change as the molar ratio of PPIX
and apoNC1-P351A increased above 1:1, indicating that the
PPIX did not bind specifically. Consistent with this notion, SEC
analysis of the 1:1 mixture revealed little 383-nm absorbance
associated with the NC1-P351A elution peak (Figure S1B). Titra-
tion of PPIX to wild-type apoNC1 at pH 6.0 showed broadened
split So¨ret peaks in the range of 300–500 nm with two maxima
at 368 and 447 nm, respectively, and weaker Q bands at 535,
555, 592, and 643 nm (Figure 2A). These features were similar
to those of free PPIX (Scolaro et al., 2002) and no saturation
behavior was observed (Figure 2B). Furthermore, the PPIX
absorbance did not co-elute with apoNC1 in SEC analyses (Fig-
ure 2C). Therefore, we conclude that a metal ion is required for a
strong DGCR8-porphyrin interaction.
Co(III)PPIX Stably Associates with DGCR8
We screened nine metalloporphyrins (Figure 1) and found that at
pH 8 only Co(III)PPIX is able to stably associate with apoNC1-
P351A, that Zn(II)PPIX only weakly binds (Figure S2), and that
the others do not seem to bind. In the titration of Co(III)PPIX,
we observed hyperporphyrin (split So¨ret) spectra, with peaks
appearing at 365, 456, and 563 nm, and a non-specific peak at
430 nm became prominent as Co(III)PPIX was added in excess
(Figure S3A). The 365-nm and 456-nm peaks are intense and
of nearly equal heights, and the a/b band at 563 nm is much
weaker. These features of the specific Co(III)PPIX-NC1-P351A
complex are similar to those seen with Fe(III) heme titration
(Barr et al., 2011). Plotting of the specific and non-specific
peak absorbance values over the Co(III)PPIX concentration
revealed a common transition at 9 mM (Figure S3B), close to
the 7.5-mM apoNC1-P351A concentration within experimental
errors, indicating that the specific binding has a stoichiometry
of one Co(III)PPIX per apoNC1-P351A dimer. SEC analyses
showed that the Co(III)PPIX absorbance co-elutes with the pro-
tein, confirming that their association is stable (Figure S3C).
Titration of Co(III)PPIX to wild-type apoNC1 at pH 8 resulted in
electronic absorption spectra remarkably similar to those from
titration to apoNC1-P351A. The peaks of the specific complex
are at 368, 456, and 563 nm and a non-specific peak at
432 nm became prominent when Co(III)PPIX is in excessLtd All rights reserved
A B C Figure 2. Protoporphyrin IX without a Metal
Center Does Not Stably Associate with
apoNC1
(A) Electronic absorption spectra of titration of
PPIX into 1.25 mM apoNC1 dimer at 0.25-mM in-
tervals, in 50 mMMES (pH 6.0), 400 mMNaCl, and
1 mM DTT. The PPIX:apoNC1 ratios of the bold
curves are indicated in italics.
(B) Absorbance values at 368 nm and 447 nm
obtained from the titration are plotted against
PPIX:apoNC1 ratios. To avoid overlapping, the
A368 values are nudged up by 0.01. In contrast
to a similar titration experiment using Fe(III)PPIX
(Barr et al., 2011), no saturation point is observed at 1:1 PPIX:apoNC1 ratio, indicating a lack of specific binding.
(C) Size exclusion chromatogram of a mixture of apoNC1 and PPIX, both at 4 mM concentration, shows little co-elution. The low 368-nm absorption in the elution
peak was contributed by the 10% heme remaining bound to the apoNC1 preparation. The chromatogram is indistinguishable from that of the apoNC1 alone.
See also Figure S1.(Figure 3A and Table 1). In SEC analyses, the A456 and slightly
less intense A432 co-eluted with the 12.5-ml protein peak (Fig-
ure 3B), indicating that Co(III)PPIX remains bound to NC1. There-
fore, we conclude that Co(III)PPIX stably binds DGCR8 at both
pH 6 and 8.
The Redox State of Cobalt Is Important for DGCR8-
CoPPIX Interaction
The cobalt in Co(III)PPIX can be reduced to Co(II). We tested if
the Co(II)PPIX can bind DGCR8. Co(II)PPIX was produced by
reducing Co(III)PPIX using dithionite and was titrated to wild-
type apoNC1. The electronic absorption spectra showed a
prominent So¨ret peak at 398 nm and a relatively broad band at
565 nm, akin to the spectrum of free Co(II)PPIX (Figure 3C and
Table 1). SEC analyses of the Co(II)PPIX-apoNC1 mixture
showed little 398-nmabsorbance in the protein elution peak (Fig-
ure 3D). Therefore, we conclude that, in sharp contrast to Co(III)
PPIX, Co(II)PPIX does not bind strongly to DGCR8. It is a com-
mon requirement for the metal ion in both CoPPIX and heme to
be in a 3+ state to stably associate with DGCR8 (herein and pub-
lished data [Barr et al., 2012]).
Co(III)PPIX Increases Pri-miRNA Processing Activity of
DGCR8
We next tested if Co(III)PPIX binding to apoNC1 can biochemi-
cally activate it for pri-miRNA processing. Uniformly 32P-labeled
pri-miRNAs were incubated with purified recombinant Drosha
and various forms of DGCR8. The latter included native Fe(III)
heme-bound NC1, apoNC1, and in vitro reconstituted NC1-
Co(III)PPIX and NC1-Fe(III)-heme complexes. The subsequent
denaturing gel and autoradiography analyses showed that,
compared with native NC1, apoNC1 displayed a deficiency in
pri-miRNA processing, with nearly no pre-miRNA produced for
pri-miR-23a, a >60% reduction of processing for pri-miR-21
and pri-miR-380, and a modest reduction (30%) for pri-miR-
30a (Figure 4, lanes 3 and 4 in all panels). Importantly, NC1 re-
constituted with Co(III)PPIX and Fe(III) heme rescued pri-miRNA
cleavage close to the levels of native NC1 for all four pri-miRNAs
(Figure 4, lanes 4 and 5 in all panels). Our previous titration exper-
iments showed that the activity of NC1 in the reconstituted assay
coincides with its binding to the pri-miRNA substrate (Faller
et al., 2010). The NC1 concentration (25 nM) used in the current
pri-miRNA processing assays is just above the K1/2 of bindingChemistry & Biology 22,(10 nM) (Quick-Cleveland et al., 2014), and this condition
should be very sensitive to changes in activity of the heme-
removed and reconstituted NC1 proteins. Therefore, our results
clearly demonstrate that Co(III)PPIX is capable of activating
DGCR8 for pri-miRNA processing, most likely by forming a com-
plex similar to that containing Fe(III) heme.
Co(III)PPIX Activates Pri-miRNA Processing in Cells
Unlike heme, CoPPIX is not degraded by heme oxygenases, the
major heme degradation pathway in mammalian cells (Kappas
and Drummond, 1986), making it potentially more useful as a
pri-miRNA processing activator. We tested if Co(III)PPIX can
activate pri-miRNA processing in human cells using a recently
developed fluorescent live-cell reporter assay that specifically
reflects changes in pri-miRNA processing efficiency (Weitz
et al., 2014). The reporter plasmid contains an mCherry expres-
sion cassette with a pri-miRNA sequence inserted in the 30-UTR,
so that cleavage of the pri-miRNA by Drosha/DGCR8 reduces
the expression of this red fluorescent protein. The plasmid also
expresses eYFP, which serves a normalization purpose. The
total mCherry and eYFP fluorescent intensities of individual cells
have a linear relationship over the wide range of expression
levels usually seen in a transient transfection experiment. The
eYFP versus mCherry slope indicates pri-miRNA processing
efficiency. This assay has been extensively validated at both pro-
tein and RNA levels and was used to demonstrate that alterna-
tions in heme biosynthesis and availability modulate pri-miRNA
processing efficiency (Weitz et al., 2014).
We used our cellular assay to determine if Co(III)PPIX can acti-
vate pri-miRNA processing in mammalian cells. HeLa cells were
adapted to grow in medium with 50%–80% of heme removed
from the serum and then transfected with the pri-miR-9-1 re-
porter. Eighteen hours after transfection, cells were treated
with SA to block heme synthesis, alone, with 0.2, 1, or 10 mM
Co(III)PPIX, or with 10 mM hemin for 10 hr. Cellular fluorescence
signals indicated that, as expected, SA treatment decreased the
slope (and thus the pri-miRNA processing efficiency) from 1.00 ±
0.02 (95% confidence interval [CI], which is shown for all fluores-
cence data) to 0.89 ± 0.03 and 10 mM hemin rescued it back
to 1.07 ± 0.03 (Figure 5A). Importantly, Co(III)PPIX increased
pri-miRNA processing efficiency in SA-treated cells in a dose-
dependent manner. The fluorescence slope was increased by
8%, 19%, and 25% in the presence of 0.2 mM, 1.0 mM, and793–802, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 795
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Figure 3. Co(III)PPIX, but Not the Co(II)
Form, Associates with apoNC1
(A) Electronic absorption spectra of Co(III)PPIX
titrated into 2 mM apoNC1 dimer at 1 mM per step,
in 50 mM MES (pH 6.0), 400 mM NaCl, and 1 mM
DTT. The absorption peak at 432 nm results from a
non-specific interaction. An absorbance spectrum
of Co(III)PPIX alone is shown as a dashed line.
(B) Size exclusion chromatogram of the recon-
stituted Co(III)PPIX-NC1 complex.
(C) Co(II)PPIX was titrated into 2.5 mM apoNC1 in
50 mM MES (pH 6.0), 400 mM NaCl, and 2 mM
sodium dithionite at 1.25 mM per step. Sodium di-
thionite obscures peaks below 350 nm because of
its high absorbance. The apoNC1 spectrum before
addition of sodium dithionite is also shown. The
absorption spectrumof Co(II)PPIXwithout proteins
is shown in the inset.
(D) Size exclusion chromatogram of apoNC1 with
Co(II)PPIX. The SEC buffer contained 50 mM
MES (pH 6.0) and 400 mM NaCl, and was de-
gassed to remove O2. The apoNC1 dimer elutes at
an expected volume. However, there is no large
accompanying absorbance at 398 nm (the Co(II)
PPIX So¨ret wavelength) or 456 nm (potential re-
oxidized Co(III)PPIX So¨ret wavelength). See also
Figures S2 and S3 and Table S1.10 mM of Co(III)PPIX, respectively (Figure 5A). Even the change
caused by the lowest concentration (0.2 mM) of CoPPIX was
highly significant (p = 0.0005). We subsequently tested if the
boost of pri-miRNA processing efficiency resulted in increased
production of mature miR-9 using qRT-PCR. With SA treatment,
the abundance of mature miR-9 was reduced to 0.64-fold
(± 0.05, SD) that of the no treatment control (Figure 5B). This
defect was rescued by both Co(III)PPIX and hemin, with the
miR-9 levels 1.15 ± 0.17-fold and 0.81 ± 0.25-fold that of the
no treatment control, respectively. The effects of Co(III)PPIX
and hemin on the reporter depend on the pri-miRNA, as the
same treatments caused little changes in fluorescence slope
when a reporter without pri-miRNA sequences was used (Fig-
ure S4). Treatment with any of these compounds is not toxic to
cells, as indicated by cell viability measurements using an MTT
assay (Figure 5C).
We performed the cellular assays in additional settings to
further corroborate the conclusion. In the experiments just
described, the changes in fluorescence slope caused by Co(III)
PPIX and hemin (8%–25%) are modest. This is caused by low
expression of DGCR8 from the endogenous loci in HeLa cells
(Weitz et al., unpublished data). With overexpression of N-termi-
nally FLAG-tagged DGCR8 (N-flag-DGCR8), the fluorescence
slope displayed by the pri-miR-9-1 reporter in cells treated
with Co(III)PPIX increased by 29%–73% relative to that of
the SA-alone control (Figure 5D). We also tested two additional
reporters that contain the pri-miR-185 and pri-miR-30a se-
quences, respectively. Upon Co(III)PPIX treatments, both re-
porters showed robust (23%–51%) increases in fluorescence
slope (Figures 5E and 5F), indicating that boost of pri-miRNA796 Chemistry & Biology 22, 793–802, June 18, 2015 ª2015 Elsevierprocessing is general across different pri-miRNA sequences.
The dose responses vary among the pri-miRNA reporters. The
increases for pri-miR-9-1 and pri-miR-185 were 29% and
23%, respectively, at 0.1 mM Co(III)PPIX, reached maxima of
73% and 51% at 1.0 mM, and decreased a little to 63% and
38% at 10 mM (Figures 5D and 5E). In contrast, the pri-miR-
30a reporter showed similar increases (44%–49%) at all three
Co(III)PPIX concentrations (Figure 5F), which suggests that this
compound may be effective at even lower concentrations for
this pri-miRNA. The increases of fluorescence slope caused by
10 mM Co(III)PPIX are either similar to or slighter higher than
that by 10 mM hemin (Figures 5D–5F). We have evidence that
with overexpression of DGCR8, pri-miRNA processing is no
longer the rate-limiting step in reporter miRNA production (Weitz
et al., data not shown) and thus mature miRNA abundance was
not examined. Our data clearly demonstrate that Co(III)PPIX is
able to generally enhance pri-miRNA processing in cells without
obvious harmful side effects.
Co(III)PPIX-Mediated Activation Compensates miRNA
Processing Deficiency Caused by Heterozygous
Deletion of Dgcr8 in Mouse Neurons
We investigated if Co(III)PPIX may be used to correct the miRNA
processing deficiency in cultured neurons. Previous studies
showed that heterozygous deletion of the Dgcr8 gene either
alone or alongwith other genes in the Df(16)A region inmice (syn-
tenic to the 1.5-Mb 22q11.2 microdeletion in humans) reduces
both the mRNA and protein levels to 50% those of the
Dgcr8+/+ in wild-type mice (Stark et al., 2008). This in turn re-
duces the maturation of certain miRNAs in the brain, includingLtd All rights reserved
Table 1. DGCR8 Binding Properties of Metalloporphyrins
MPPIX
So¨ret Peak,
Free (nm)
So¨ret Peak,
Bound (nm)
Stably Bind
DGCR8
Activate Pri-miRNA
Processing
Fe(III) 384 367, 450 Yes Yes
Fe(II) 390 ND No No
Co(III) 418 368, 456 Yes Yes
Co(II) 397 398 No ND
The properties of Fe(III) and Fe(II) heme were known from a previous
study (Barr et al., 2012) and are shown for comparison. ND, not deter-
mined.miR-185 and miR-134, which are important for dendritic spine
development (Stark et al., 2008; Xu et al., 2013). We prepared
primary cortical neurons from Dgcr8+/– pups and their wild-
type littermate controls at embryonic day 17. These neurons
were cultured in vitro and treated from 1 day in vitro (DIV) for
2 days with 0.2, 2, and 20 mMCo(III)PPIX. We then extracted total
RNAs and measured the miRNA abundance. Similar to what has
been reported previously (Xu et al., 2013), the miR-185 levels
in the Dgcr8+/– neurons decreased by 31% compared with the
Dgcr8+/+ neurons (Figure 6A). Treatment with Co(III)PPIX at all
three concentrations increased the miR-185 expression (Fig-
ure 6A). Even at the lowest concentration of 0.2 mM, the increase
of miR-185 to 89% of wild-type is statistically significant. At
20 mM, Co(III)PPIX restored miR-185 to a level indistinguishable
from that of the wild-type. Co(III)PPIX at 20 mM also significantly
increased the expression of another miRNA, miR-134, which is
negatively affected by Dgcr8 haploinsufficiency in cultured pri-
mary neurons (Figure 6B). The neurons all looked healthy with
processes developing under all conditions (Figure 6C). Impor-
tantly, little activated (cleaved) caspase-3 was detected, indi-
cating lack of apoptosis in the treated cells. These experiments
demonstrate that Co(III)PPIX is capable of correcting the miRNA
processing deficiency caused by reduced Dgcr8 gene dosage
and thus pave the way to further explore the value of this metal-
loporphyrin in treating 22q11.2DS and other diseases linked to
deficient miRNA processing.
DISCUSSION
Here we identify Co(III)PPIX as an activator of pri-miRNA
processing. This activator mimics the required heme cofactor
of DGCR8 but is not subjected to degradation by heme oxy-
genases. DGCR8 and its homologs constitute a unique class
of heme protein in that they use two cysteine side chains
(Cys352 from both subunits in a dimer) to ligate the heme iron
(Barr et al., 2011, 2012). At least one (likely both) of the Cys352
side chains is in the deprotonated thiolate state. The electron-
rich environment contributes to a tremendous preference for
DGCR8 to bind Fe(III) heme over Fe(II) heme. The human
DGCR8 does not dissociate with Fe(III) heme substantially
even after incubation at room temperature for 4 days (koff <
33 106 s1) with large excess of heme scavenger apomyoglo-
bin (Barr et al., 2011). In contrast, the dissociation rate of Fe(II)
heme from DGCR8 cannot be measured using the stop flow
method (koff > 100 s
1) (Barr et al., 2012). Thus, a single electron
(the difference between Fe(III) and Fe(II)) causes a >107-foldChemistry & Biology 22,change in koff. The reduction of the heme iron causes loss of
both cysteine ligands (Barr et al., 2012), resulting in near elimina-
tion of DGCR8 binding and activation activities.
Among the metalloporphyrins with the central atoms high-
lighted in Figure 1B, only Co(III)PPIX and Fe(III)PPIX (heme) are
capable of stably binding DGCR8 and activating its miRNA pro-
cessing activity. Cobalt and iron in the 3+ state contain 5 and 6
electrons in their d shells, respectively, leaving those orbitals
approximately half empty and thereby favoring the octahedral
coordination. Our previous electron paramagnetic resonance
study indicated that the Fe(III) in DGCR8 is in a low-spin S = ½
state, with one unpaired electron (Barr et al., 2011). The spin
state of Co(III)PPIX in DGCR8 remains to be determined. Both
Co and Fe are redox active with another most accessible state
being 2+ when chelated by porphyrins. Similar to Fe(II)PPIX,
the Co(II)PPIX does not stably bind DGCR8. The stringent metal
ion and redox state requirements are likely to be demanded
by the dual cysteine-ligation of DGCR8 and the electron-rich
environment.
A key difference between CoPPIX and heme is that CoPPIX
is not degraded by the heme degradation enzymes, heme oxy-
genases (Kikuchi et al., 2005). This property makes Co(III)PPIX
much more stable in the body. Subcutaneous injection to rats
results in retention of the compound in spleen, gonads, lung,
and thymus for up to 4 weeks (Rosenberg, 1993). Furthermore,
Kappa and colleagues treated rats with CoPPIX and observed
a substantial decrease in body fat contents and overall body
weight (Galbraith and Kappas, 1989). Either subcutaneous injec-
tion or intracerebroventricular injection into the brain was effec-
tive. The effects persisted over a long period, with those from a
single intracerebroventricular dosage at 0.2 or 0.4 mmol per kg
of body weight lasting strikingly for over 300 days. These effects
were not produced by cobalt chloride, heme, or other metallo-
porphyrins tested and therefore appear to be specific to CoPPIX.
No histological abnormalities were observed in the brain, sug-
gesting that administration of CoPPIX at low dosages may be
safe for treating diseases such as 22q11.2DS. In addition, there
has been a substantial body of work trying to identify the in vivo
targets of CoPPIX that contribute to the slimming effects,
including heme oxygenase-1 (HO-1) (Csongradi et al., 2012)
and nitric oxide synthase (Li et al., 2006). Our study suggests
that boost of miRNA processing is another major effect of
CoPPIX.
CoPPIX has been shown to potently induce the expression of
HO-1, even though the compound itself is a competitive inhibitor
of heme oxygenase enzymes (Dercho et al., 2006; Shan et al.,
2000, 2006). Previous studies showed that 5–10 mM of CoPPIX
is needed to induce HO-1 expression (Dercho et al., 2006;
Shan et al., 2000, 2006). In the current study, we show that
Co(III)PPIX is effective in activating pri-miRNA processing in hu-
man cells at concentrations as low as 0.2 mM. Thus, it should be
possible to activate DGCR8without substantially inducing HO-1.
On the other hand, induction of HO-1 has major cytoprotective
and other beneficial physiological effects (Motterlini and Foresti,
2014; Wu et al., 2011). These effects are elicited by the products
of the heme degradation reaction: biliverdin is a potent anti-
oxidant and carbon monoxide has anti-inflammatory and
anti-apoptotic activities. Therefore, activation of HO-1 by
CoPPIX has been proposed as a potential therapeutic strategy793–802, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 797
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Figure 4. Co(III)PPIX Activates DGCR8 for Pri-miRNA Processing In Vitro
(A–D) Denaturing gel analyses of cleavage assays of (A) pri-miR-23a, (B) pri-miR-21, (C) pri-miR-380, and (D) pri-miR-30a. The cleavage reactions contained trace
amounts of uniformly 32P-labeled pri-miRNAs, recombinant His6-Drosha
390–1374 and the various forms of DGCR8 proteins (25 nM dimer). NC1 is the native Fe(III)
heme-bound dimer. apoNC1 is NC1with the >90% of heme removed. The reactions labeled with +Fe(III)PPIX and +Co(III)PPIX contained apoNC1 incubated with
equimolar of Fe(III) heme or Co(III)PPIX, respectively. Fractions of pri-miRNAs converted to pre-miRNAs are plotted asmeans ± SD (n = 3 for pri-miR-23a, pri-miR-
21, and pri-miR-380; n = 4 for pri-miR-30a). Asterisks indicate statistically significant activation of apoNC1 (**p% 0.01; *0.01 < p% 0.05).for treating cardiovascular diseases and obesity (Csongradi
et al., 2012; Galbraith and Kappas, 1990). It may be beneficial
to activate both pri-miRNA processing and HO-1 using modest
dosages of Co(III)PPIX. Increased heme oxygenase expression
and activity would reduce the intracellular heme availability,
which would in turn be expected to reduce pri-miRNA process-
ing. At 10 or 20 mM of Co(III)PPIX, direct activation of DGCR8
appears to have a dominating effect on enhancing pri-miRNA
processing efficiency over the potential indirect inhibition via
HO-1 induction (Figures 5 and 6). The tight interaction between
DGCR8 and Co(III)PPIX must have contributed to this overall
positive effect of Co(III)PPIX on pri-miRNA processing.
CoPPIX shares major chemical properties with heme and thus
is able to interact with additional heme proteins and possibly
affect their respective biological pathways. For example,
CoPPIX has been shown to inhibit the rate-limiting heme synthe-
sis enzyme d-aminolevulinic acid synthase (Schoenfeld et al.,
1984). The combination of heme synthesis inhibition and degra-
dation (the latter from induction of HO-1) causes a reduction of
cytochrome P450 in the liver (Drummond and Kappas, 1982).
Cobalt-substituted cytochrome P450cam, cystathionine b-syn-
thase, and horseradish peroxidase can be biochemically recon-
stituted using the corresponding apoproteins andCoPPIX (Smith
et al., 2011; Wagner et al., 1981; Wang et al., 1977), although it is
not clear whether CoPPIX is incorporated to these heme proteins798 Chemistry & Biology 22, 793–802, June 18, 2015 ª2015 Elsevierin vivo. Therefore, caution should be exercisedwhen considering
CoPPIX in long-term systemic treatments, especially at medium
to high concentrations.
In summary,we found thatCo(III)PPIX bindsDGCR8 tightly and
activates its pri-miRNA processing activity potently (Table 1). We
show that this compound is effective in correctingpri-miRNApro-
cessing defects by activating the DGCR8 protein in mouse neu-
rons that mimic the DGCR8 haploinsufficiency in 22q11.2DS
(Stark et al., 2008; Xu et al., 2013). Co(III)PPIX is not degraded
by the heme degradation enzymes and thus has highly favorable
pharmacokinetic half-lives (Galbraith and Kappas, 1989; Rosen-
berg, 1993). It works at low concentration, allowing the interac-
tion with other heme proteins and potential undesired effects to
be limited. These properties qualify Co(IIII)PPIX as a potential
therapeutic for diseases in which pri-miRNA processing defi-
ciency is involved. As pri-miRNA processing is highly regulated
in broad biological contexts (Davis and Hata, 2009; Ha and
Kim, 2014), Co(III)PPIX will also be useful as a research tool.
SIGNIFICANCE
miRNAs are extensively involved in development and cell
physiology, and reduced miRNA production has been linked
to many diseases. In cancers, decreased expression of
miRNAprocessing factorshasbeenextensivelydocumented.Ltd All rights reserved
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Figure 5. Live-Cell Pri-miRNA Processing Assay Shows that Co(III)PPIX Activates Pri-miRNA Processing without Inducing Cytotoxicity
HeLa cells were cultured in heme-depleted medium, transfected with the pri-miR-9-1 reporter, treated for 10 hr with succinylacetone (1 mM) either alone or
together with Co(III)PPIX or hemin at the indicated concentrations.
(A) Normalized eYFP/mCherry fluorescence slopes (± 95% CI).
(B) Abundance of mature miR-9 normalized by that of b-actin mRNA (mean ± SD, n = 4; **p% 0.01).
(C) MTT assays showed little cytotoxicity (mean ± SD, n = 4).
(D–F) Reporter assays were performed similar to as described above, except that the N-flag-DGCR8 expression plasmid was cotransfected with the reporters,
that the pri-miR-9-1 (D), pri-miR-185 (E), and pri-miR-30a (F) reporters were used, and that SA, Co(III)PPIX, and heminwere added before transfection. Plotted are
normalized eYFP/mCherry fluorescence slopes ± 95% CI. See also Figure S4.Another disease, 22q11.2DS, is caused by the most common
human chromosome microdeletion, with an incidence of 1 in
2,000–4,000 live births. Concrete evidence has demonstrated
that these miRNA processing defects directly contribute to
pathogenesis. However, it has not been possible to correct
thempharmacologically. Here usinga combinedbiochemical
and cellular approach, we identify a miRNA processing acti-
vator, cobalt(III) protoporphyrin IX (PPIX). This compound
binds and activates DGCR8 by mimicking its essential heme
cofactor but is not degraded by heme degradation enzymes.
Co(III)PPIXcorrects themiRNAprocessingdeficiencycaused
by heterozygous deletion of DGCR8 in cultured mouse neu-
rons. Our study demonstrates that it is possible to compen-
sate miRNA processing defects by activating the processing
proteins.EXPERIMENTAL PROCEDURES
Materials
Hemin and Co(III)PPIX were purchased from Sigma. All other metalloporphyr-
ins were obtained from Frontier Scientific.
Expression and Purification of Recombinant DGCR8
Fe(III) NC1, apoNC1, and apoNC1 P351A proteins were purified as described
previously (Barr et al., 2011, 2012). Briefly, the constructs were expressed inChemistry & Biology 22,the pET-24a+ vector in E. coli and purified using cation exchange chromatog-
raphy followed by SEC. The SECbuffer contained 20mMTris (pH 8.0), 400mM
NaCl, and 1 mM DTT. Reduction of the Fe(III) NC1 was accomplished using
2 mM sodium dithionite in 50 mM 2-(N-morpholino)ethanesulfonic acid
(MES) (pH 6.0), 400 mM NaCl, and 1 mM DTT.
DGCR8 Porphyrin-Binding Assay
All porphyrin solutions were made fresh on the day of use and stored at%4C.
PPIX was initially dissolved in 50% DMSO and 50% 0.1 M NaOH, concentra-
tion wasmeasured (1mM), and diluted into the final binding buffer (pH 6 or 8).
Metalloporphyrins were initially dissolved in 0.1 M NaOH and then diluted
to 100-mM stocks using binding buffer. The concentrations were determined
either gravimetrically (Rh and In) or using published extinction coefficients.
Several published absorbance peaks and extinction coefficient values are
listed in Table S1.
The porphyrin-binding reaction buffer contained 1 mM DTT, 400 mM NaCl,
and the buffer was either 50mMMES (pH 6.0) (for wild-type apoNC1) or 20mM
Tris (pH 8.0) (for apoNC1 P351A). Absorbance spectra were collected using
either a Varian Cary 300 Bio spectrophotometer with bandwidth set to 1 nm
(Figures 2A, 3A, and 3C), or a DU800 spectrophotometer (Beckman-Coulter,
bandwidth%1.8 nm) (Figures S1–S3).
Reconstituted Pri-miRNA Processing Assays
The assays were done as described previously (Barr et al., 2012). The reac-
tions were incubated at 37C for either 30 min (pri-miR-23a and pri-miR-
30a) or 45 min (pri-miR-21 and pri-miR-380), and were analyzed using 15%
acrylamide, 7 M urea denaturing gels, and autoradiography. The bands were
quantified using the ImageQuant software (GE Healthcare). The intensities of
pre-miRNAs were converted to the equivalents of pri-miRNAs by multiplying793–802, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 799
Figure 6. Co(III)PPIX Restores Deficient miRNA Expression Caused by Heterozygous Deletion of the Dgcr8 Gene in Mice
Primary cortical neurons dissected from Dgcr8+/– mouse embryos and their wild-type (WT) littermates were treated with Co(III)PPIX at the indicated concen-
trations between DIV 1 and 3, for 48 hr.
(A and B) Mature miR-185 (A) andmiR-134 (B) levels after normalization to that of theGapdhmRNA. The miR-134 data at lower Co(III)PPIX concentrations did not
reach statistical significance and thus are not shown. Each plotted value is average ± SEM from seven independent experiments using seven animals for each
genotype. Select p values are calculated using the two-tailed Student’s t test and are indicated on the graph.
(C) Images of the treated and control neurons with processes visualized via MAP2 staining (shown in green).the ratio of the numbers of 32P-containing residues in the pri-miRNA and pre-
miRNA. p values were calculated using the two-tailed Student’s t test and the
Mann-Whitney U test.
Cellular Pri-miRNA Processing Assay
The cellular assays were performed as described previously (Mukherji et al.,
2011; Weitz et al., 2014). Briefly, cells were grown in heme-depleted medium
for 24 hr before splitting into smaller plates for both imaging and RNA anal-
ysis. For the experiments in Figures 5A and 5B, cells were transfected with
the reporter. Eighteen hours after transfection, 1 mM SA, either alone or
with 0.2, 1, or 10 mM Co(III)PPIX, or 10 mM hemin, was added to the cells,
and 1 mg/ml doxycycline was also added to induce expression of reporters.
Co(III)PPIX and hemin were dissolved in DMSO shortly before addition to
the cell cultures. After 10 hr of treatment, cells were used either for imaging
or for total RNA extraction. Imaging and data analysis were performed as
described (Weitz et al., 2014). Total RNAs were extracted using the miRNeasy
mini kit (Qiagen). Taqman qRT-PCR assays (Life Technologies) were used to
measure mature miR-9 and b-actin mRNA levels. A similar procedure was
used for the experiments in Figures 5D–5F, except that the N-flag-DGCR8-800 Chemistry & Biology 22, 793–802, June 18, 2015 ª2015 Elsevierexpression plasmid or the pCMV-Tag2A vector (as a control) was included
in the transfection together with the reporter. To ensure that N-flag-DGCR8
was expressed under the heme-deficient and/or porphyrin-treated condi-
tions, SA, Co(III)PPIX, hemin were added 2 hr before the transfection. Doxy-
cycline was added shortly after the transfection. Imaging was done 16–18 hr
after transfection.
Treatment of Mouse Dgcr8+/– Neurons Using Co(III)PPIX
All animal protocols used in this study are approved by Columbia University
Institutional Animal Care and Use Committee. Dgcr8+/– mice have been
described previously (Stark et al., 2008) and have been backcrossed into
C57BL/6J background for over ten generations. After embryonic dissection,
dissociated neurons from individual pups were cultured at 2 x 106 neurons
per condition. At DIV 1, cells were treated with Co(III)PPIX or DMSO (no
porphyrin control) as indicated in Figure 6. Co(III)PPIX was dissolved in
DMSO. At DIV 3, total RNA was isolated using miRNeasy mini kit (Qiagen).
Taqman qRT-PCR assays (Life Technologies) were used to measure mature
miR-185, miR-134, and Gapdh mRNA levels, as described previously (Stark
et al., 2008; Xu et al., 2013).Ltd All rights reserved
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and one table and can be
found with this article online at http://dx.doi.org/10.1016/j.chembiol.2015.
05.015.
AUTHOR CONTRIBUTIONS
I.B. and F.G. conceived the project, I.B. performed all the biochemical exper-
iments, S.H.W. and S.W. are responsible for the HeLa cells experiments, T.A.,
P.H., M.K., and J.A.G. are responsible for the mouse neuron experiments. I.B.,
S.H.W., and F.G. wrote the article with input from other authors.
ACKNOWLEDGMENTS
We thank J. Valentine and K. Barnese for use of the anaerobic chamber and J.
Feigon for use of spectrophotometer. This project was supported by NIH
Grants GM080563 (to F.G.), MH67068 (M.K. and J.A.G.), MH077235
(J.A.G.), T32GM008496 (S.H.W.). S.H.W. and I.B. were supported by UCLA
Dissertation Year Fellowships. S.W. acknowledges support fromWillard Chair
funds.
Received: December 11, 2014
Revised: May 1, 2015
Accepted: May 20, 2015
Published: June 18, 2015
REFERENCES
Barr, I., and Guo, F. (2014). Primary microRNA processing assay reconstituted
using recombinant Drosha and DGCR8. Methods Mol. Biol. 1095, 73–86.
Barr, I., Smith, A.T., Senturia, R., Chen, Y., Scheidemantle, B.D., Burstyn, J.N.,
and Guo, F. (2011). DiGeorge critical region 8 (DGCR8) is a double-cysteine-
ligated heme protein. J. Biol. Chem. 286, 16716–16725.
Barr, I., Smith, A.T., Chen, Y., Senturia, R., Burstyn, J.N., and Guo, F. (2012).
Ferric, not ferrous, heme activates RNA-binding protein DGCR8 for primary
microRNA processing. Proc. Natl. Acad. Sci. USA 109, 1919–1924.
Beveridge, N.J., and Cairns, M.J. (2012). MicroRNA dysregulation in schizo-
phrenia. Neurobiol. Dis. 46, 263–271.
Csongradi, E., Docarmo, J.M., Dubinion, J.H., Vera, T., and Stec, D.E. (2012).
Chronic HO-1 induction with cobalt protoporphyrin (CoPP) treatment in-
creases oxygen consumption, activity, heat production and lowers body
weight in obese melanocortin-4 receptor-deficient mice. Int. J. Obes. 36,
244–253.
Davis, B.N., and Hata, A. (2009). Regulation of microRNA biogenesis: a miRiad
of mechanisms. Cell Commun. Signal. 7, 18.
Denli, A.M., Tops, B.B., Plasterk, R.H., Ketting, R.F., and Hannon, G.J. (2004).
Processing of primary microRNAs by the Microprocessor complex. Nature
432, 231–235.
Dercho, R.A., Nakatsu, K., Wong, R.J., Stevenson, D.K., and Vreman, H.J.
(2006). Determination of in vivo carbon monoxide production in laboratory an-
imals via exhaled air. J. Pharmacol. Toxicol. Methods 54, 288–295.
Drummond, G.S., and Kappas, A. (1982). The cytochrome P-450-depleted an-
imal: an experimental model for in vivo studies in chemical biology. Proc. Natl.
Acad. Sci. USA 79, 2384–2388.
Faller, M., Matsunaga, M., Yin, S., Loo, J.A., and Guo, F. (2007). Heme is
involved in microRNA processing. Nat. Struct. Mol. Biol. 14, 23–29.
Faller, M., Toso, D., Matsunaga, M., Atanasov, I., Senturia, R., Chen, Y., Zhou,
Z.H., and Guo, F. (2010). DGCR8 recognizes primary transcripts of microRNAs
through highly cooperative binding and formation of higher-order structures.
RNA 16, 1570–1583.
Fenelon, K., Mukai, J., Xu, B., Hsu, P.K., Drew, L.J., Karayiorgou, M.,
Fischbach, G.D., Macdermott, A.B., and Gogos, J.A. (2011). Deficiency of
Dgcr8, a gene disrupted by the 22q11.2 microdeletion, results in altered
short-term plasticity in the prefrontal cortex. Proc. Natl. Acad. Sci. USA 108,
4447–4452.Chemistry & Biology 22,Galbraith, R.A., and Kappas, A. (1989). Regulation of food intake and body
weight by cobalt porphyrins in animals. Proc. Natl. Acad. Sci. USA 86,
7653–7657.
Galbraith, R.A., and Kappas, A. (1990). Cobalt-protoporphyrin suppresses
expression of genetic obesity in homozygous (fa/fa) Zucker rats.
Pharmacology 41, 292–298.
Gong, M., Chen, Y., Senturia, R., Ulgherait, M., Faller, M., and Guo, F. (2012).
Caspases cleave and inhibit the microRNA processing protein DiGeorge crit-
ical region 8. Protein Sci. 21, 797–808.
Gregory, R.I., Yan, K.P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch,
N., and Shiekhattar, R. (2004). TheMicroprocessor complexmediates the gen-
esis of microRNAs. Nature 432, 235–240.
Ha, M., and Kim, V.N. (2014). Regulation of microRNA biogenesis. Nat. Rev.
Mol. Cell Biol. 15, 509–524.
Han, J., Lee, Y., Yeom, K.H., Kim, Y.K., Jin, H., and Kim, V.N. (2004). The
Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 18,
3016–3027.
Herbert, K.M., Pimienta, G., DeGregorio, S.J., Alexandrov, A., and Steitz, J.A.
(2013). Phosphorylation of DGCR8 increases its intracellular stability and
induces a progrowth miRNA profile. Cell Rep. 5, 1070–1081.
Kappas, A., and Drummond, G.S. (1986). Control of heme metabolism with
synthetic metalloporphyrins. J. Clin. Invest. 77, 335–339.
Karayiorgou, M., Simon, T.J., and Gogos, J.A. (2010). 22q11.2 microdeletions:
linking DNA structural variation to brain dysfunction and schizophrenia. Nat.
Rev. Neurosci. 11, 402–416.
Kikuchi, G., Yoshida, T., and Noguchi, M. (2005). Heme oxygenase and heme
degradation. Biochem. Biophys. Res. Commun. 338, 558–567.
Kumar, M.S., Lu, J., Mercer, K.L., Golub, T.R., and Jacks, T. (2007). Impaired
microRNA processing enhances cellular transformation and tumorigenesis.
Nat. Genet. 39, 673–677.
Landthaler, M., Yalcin, A., and Tuschl, T. (2004). The human DiGeorge syn-
drome critical region gene 8 and its D. melanogaster homolog are required
for miRNA biogenesis. Curr. Biol. 14, 2162–2167.
Li, M.Y., Vizzard, M.A., Jaworski, D.M., and Galbraith, R.A. (2006). The weight
loss elicited by cobalt protoporphyrin is related to decreased activity of nitric
oxide synthase in the hypothalamus. J. Appl. Physiol. 100, 1983–1991.
Merritt, W.M., Lin, Y.G., Han, L.Y., Kamat, A.A., Spannuth, W.A., Schmandt,
R., Urbauer, D., Pennacchio, L.A., Cheng, J.F., Nick, A.M., et al. (2008).
Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J.
Med. 359, 2641–2650.
Mori, M., Triboulet, R., Mohseni, M., Schlegelmilch, K., Shrestha, K., Camargo,
F.D., and Gregory, R.I. (2014). Hippo signaling regulates microprocessor and
links cell-density-dependent miRNA biogenesis to cancer. Cell 156, 893–906.
Motterlini, R., and Foresti, R. (2014). Heme oxygenase-1 as a target for drug
discovery. Antioxid. Redox Signal. 20, 1810–1826.
Mukherji, S., Ebert, M.S., Zheng, G.X., Tsang, J.S., Sharp, P.A., and van
Oudenaarden, A. (2011). MicroRNAs can generate thresholds in target gene
expression. Nat. Genet. 43, 854–859.
Quick-Cleveland, J., Jacob, J.P., Weitz, S.H., Shoffner, G., Senturia, R., and
Guo, F. (2014). The DGCR8 RNA-binding heme domain recognizes primary
microRNAs by clamping the hairpin. Cell Rep. 7, 1994–2005.
Rosenberg, D.W. (1993). Pharmacokinetics of cobalt chloride and cobalt-pro-
toporphyrin. Drug Metab. Dispos. 21, 846–849.
Schoenfeld, N., Wysenbeek, A.J., Greenblat, Y., Epstein, O., Atsmon, A., and
Tschudy, D.P. (1984). The effects of metalloporphyrins, porphyrins and metals
on the activity of delta-aminolevulinic acid synthase in monolayers of chick
embryo liver cells. Biochem. Pharmacol. 33, 2783–2788.
Schofield, C.M., Hsu, R., Barker, A.J., Gertz, C.C., Blelloch, R., andUllian, E.M.
(2011). Monoallelic deletion of the microRNA biogenesis gene Dgcr8 produces
deficits in the development of excitatory synaptic transmission in the prefrontal
cortex. Neural Dev. 6, 11.793–802, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 801
Scolaro, L.M., Castriciano, M., Romeo, A., Patane, S., Cefali, E., and Allegrini,
M. (2002). Aggregation behavior of protoporphyrin IX in aqueous solutions:
clear evidence of vesicle formation. J. Phys. Chem. B 106, 2453–2459.
Senturia, R., Faller, M., Yin, S., Loo, J.A., Cascio, D., Sawaya,M.R., Hwang, D.,
Clubb, R.T., and Guo, F. (2010). Structure of the dimerization domain of
DiGeorge critical region 8. Protein Sci. 19, 1354–1365.
Shan, Y., Pepe, J., Lu, T.H., Elbirt, K.K., Lambrecht, R.W., and Bonkovsky, H.L.
(2000). Induction of the heme oxygenase-1 gene by metalloporphyrins. Arch.
Biochem. Biophys. 380, 219–227.
Shan, Y., Lambrecht, R.W., Donohue, S.E., and Bonkovsky, H.L. (2006). Role
of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt
protoporphyrin. FASEB J. 20, 2651–2653.
Shiohama, A., Sasaki, T., Noda, S., Minoshima, S., and Shimizu, N. (2003).
Molecular cloning and expression analysis of a novel gene DGCR8 located
in the DiGeorge syndrome chromosomal region. Biochem. Biophys. Res.
Commun. 304, 184–190.
Smith, A.T., Majtan, T., Freeman, K.M., Su, Y., Kraus, J.P., and Burstyn, J.N.
(2011). Cobalt cystathionine beta-synthase: a cobalt-substituted heme protein
with a unique thiolate ligation motif. Inorg. Chem. 50, 4417–4427.802 Chemistry & Biology 22, 793–802, June 18, 2015 ª2015 ElsevierStark, K.L., Xu, B., Bagchi, A., Lai, W.S., Liu, H., Hsu, R., Wan, X., Pavlidis, P.,
Mills, A.A., Karayiorgou, M., et al. (2008). Altered brain microRNA biogenesis
contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat.
Genet. 40, 751–760.
Wada, T., Kikuchi, J., and Furukawa, Y. (2012). Histone deacetylase 1
enhances microRNA processing via deacetylation of DGCR8. EMBO Rep.
13, 142–149.
Wagner, G.C., Gunsalus, I.C., Wang, M.Y., and Hoffman, B.M. (1981). Cobalt-
substituted cytochrome P-450cam. J. Biol. Chem. 256, 6266–6273.
Wang, M.Y., Hoffman, B.M., and Hollenberg, P.F. (1977). Cobalt-substituted
horseradish peroxidase. J. Biol. Chem. 252, 6268–6275.
Weitz, S.H., Gong, M., Barr, I., Weiss, S., and Guo, F. (2014). Processing of
microRNA primary transcripts requires heme in mammalian cells. Proc. Natl.
Acad. Sci. USA 111, 1861–1866.
Wu, M.L., Ho, Y.C., Lin, C.Y., and Yet, S.F. (2011). Heme oxygenase-1 in
inflammation and cardiovascular disease. Am. J. Cardiovasc. Dis. 1, 150–158.
Xu, B., Hsu, P.K., Stark, K.L., Karayiorgou, M., and Gogos, J.A. (2013).
Derepression of a neuronal inhibitor due to miRNA dysregulation in a schizo-
phrenia-related microdeletion. Cell 152, 262–275.Ltd All rights reserved
